Henry Schein Q3 2026 Earnings: Dental Growth Supports Higher Guidance
Henry Schein reported Q3 2026 net sales of $3.47 billion, up 4.0% year over year, while non-GAAP diluted EPS increased 13.0% to $1.56, driven by U.S. dental merchandise growth and market-share gains. Operating income grew 17.7%, and adjusted EBITDA margin expanded 40 basis points to 9.24%. Consequently, the company raised its full-year non-GAAP EPS guidance to $5.50–$5.56 and upgraded its adjusted EBITDA growth outlook to high single digits. Key risks include declining operating cash flow, rising accounts receivable, higher borrowings associated with share repurchases, and reliance on underlying operating execution rather than nonrecurring tariff benefits.
Henry Schein (Nasdaq: HSIC) reported Q3 2026 net sales of $3.47 billion, up 4.0% year over year, while GAAP diluted EPS rose 26.2% to $1.06. For the quarter ended September 26, non-GAAP diluted EPS increased 13.0% to $1.56 and adjusted EBITDA margin expanded 40 basis points to 9.24%. U.S. dental merchandise sales growth of 8.6%, driven primarily by volume and market-share gains, was the main operating driver behind the quarter and the higher full-year guidance.
Core Earnings Data
Revenue growth consisted of 3.1% internal growth in local currencies, a 0.7% contribution from acquisitions, and a 0.2% foreign-exchange benefit. Gross profit and operating income both grew faster than sales, producing higher gross and operating margins.
At the same time, quarterly operating cash flow declined despite higher earnings. The following figures are in USD millions except for per-share data.
| Metric | Q3 2026 | Q3 2025 | Year-Over-Year Change |
|---|---|---|---|
| Net sales | $3,471 | $3,339 | +4.0% |
| Gross profit / margin | $1,105 / approximately 31.8% | $1,026 / approximately 30.7% | +7.7% / approximately +110 bps |
| Operating income / margin | $193 / approximately 5.6% | $164 / approximately 4.9% | +17.7% / approximately +65 bps |
| Net income attributable to Henry Schein | $119 | $101 | +17.8% |
| GAAP diluted EPS | $1.06 | $0.84 | +26.2% |
| Non-GAAP diluted EPS | $1.56 | Not stated | +13.0% |
| Adjusted EBITDA / margin | $321 / 9.24% | $295 / 8.84% implied | +8.8% / +40 bps |
| Operating cash flow | $161 | $174 | -7.5% |
Lower restructuring and related costs helped operating profit: these costs declined to $22 million from $34 million, even as selling, general and administrative expenses increased to $819 million from $760 million.
Business and Segment Performance
Growth varied considerably across Henry Schein’s businesses. Global dental merchandise and technology produced the highest reported growth, while value-added services declined and medical distribution posted only modest expansion. Internal growth is measured in local currencies and excludes acquisitions.
U.S. dental merchandise sales increased 8.6%, primarily because of higher volume associated with market-share gains in what management described as a stable market.
| Business | Reported Growth | Internal Growth | Main Detail |
|---|---|---|---|
| Global Distribution and Value-Added Services | +3.7% | +2.9% | Acquisitions added 0.5%; currency added 0.3% |
| Global Dental Distribution merchandise | +7.0% | +5.1% | U.S. merchandise sales rose 8.6% |
| Global Dental Distribution equipment | +2.3% | +2.4% | Similar reported and internal growth |
| Global Medical Distribution | +1.1% | +1.0% | Modest growth |
| Global Value-Added Services | -4.8% | -4.8% | Declined on both measures |
| Global Specialty Products | +6.1% | +3.4% | Acquisitions contributed 2.6% |
| Global Technology | +5.2% | +6.5% | A business disposal reduced reported growth by 1.3% |
Technology’s internal growth exceeded its reported rate because of the business disposal. Specialty Products showed the opposite pattern, with acquisitions accounting for a meaningful portion of reported growth.
Tariff Items and Buybacks Shaped the EPS Growth Rate
The headline 13.0% increase in non-GAAP EPS included different benefits in the two comparison periods. Q3 2026 contained a $0.19-per-share net benefit from tariff refunds, while Q3 2025 included a $0.23-per-share remeasurement gain.
Excluding both items, non-GAAP diluted EPS was $1.37 compared with $1.15 a year earlier, an increase of 19.1%. This comparison indicates that the company’s adjusted earnings growth was not solely dependent on the current-quarter tariff refund, even though that benefit contributed materially to reported EPS.
Share repurchases also widened the gap between earnings growth and per-share growth. Net income attributable to Henry Schein increased 17.8%, while GAAP diluted EPS rose 26.2%; diluted weighted-average shares declined approximately 7.0% to 112.5 million from 121.0 million.
Cash Flow, Balance Sheet, and Capital Allocation
Operating cash flow decreased to $161 million from $174 million despite higher net income. Accounts receivable used $122 million of cash during the quarter, compared with $98 million a year earlier, while the cash contribution from accounts payable and accrued expenses declined to $89 million from $99 million.
At September 26, cash and cash equivalents were $184 million, up from $156 million at the end of fiscal 2025. Accounts receivable increased to $1.88 billion from $1.65 billion over the same period, while inventories rose to $2.05 billion from $2.00 billion.
Bank credit lines plus current and long-term debt totaled approximately $3.52 billion, up from $3.11 billion at the end of fiscal 2025. During Q3, Henry Schein repurchased approximately 1.4 million shares for $125 million at an average price of $86.67. Year-to-date repurchases totaled $450 million, and $330 million remained under the authorization at quarter-end.
FY2026 Guidance
Henry Schein raised its full-year non-GAAP EPS outlook and upgraded its adjusted EBITDA growth expectation, while leaving its sales growth range unchanged. The update reflects improved operating performance and the Q3 tariff refund benefit, while also incorporating targeted, limited Q4 investments intended to support growth in 2027.
| Metric | Updated FY2026 Guidance | Previous Guidance | Change |
|---|---|---|---|
| Non-GAAP diluted EPS | $5.50–$5.56 | $5.29–$5.39 | Raised |
| Total sales growth | 4.5%–5.5% | 4.5%–5.5% | Unchanged |
| Adjusted EBITDA growth | High single digits | Mid-to-high single digits | Raised |
The guidance assumes no significant additional tariff refunds or remeasurement gains for the remainder of 2026 and generally stable foreign-exchange rates. It applies to current continuing operations and excludes items including restructuring costs, acquired-intangible amortization, certain implementation costs, and litigation settlements.
Recent Insider Transactions
The supplied transaction details included one purchase and two sales with explicit cash values among the most recent entries. Other recent entries consisted mainly of stock gifts and an award reported at zero value.
| Date | Insider | Role | Transaction | Price per Share | Reported Value |
|---|---|---|---|---|---|
| May 11, 2026 | Daniel William K | Director | Indirect purchase | $69.19 | $691,900 |
| March 19, 2026 | Popeck Thomas C | Officer | Direct sale | $72.79 | $98,630 |
| March 10, 2026 | Kuehn Kurt P | Director | Direct sale | $78.96 | $224,565 |
The accompanying six-month summary showed zero purchases and zero sales despite listing the May purchase in the detailed ledger, indicating a possible difference in data timing or classification. These transactions by themselves do not establish insiders’ views about the company’s prospects.
Risks Investors Need to Watch
- Uneven business growth: U.S. dental merchandise was the main growth driver, but value-added services declined 4.8% and medical distribution grew only 1.1%. A slowdown in dental market-share gains would expose the weaker performance elsewhere in the portfolio.
- Nonrecurring earnings items: Q3 EPS included a $0.19-per-share tariff refund benefit. Guidance assumes no significant additional refunds or remeasurement gains for the remainder of 2026, increasing the importance of underlying operating execution.
- Cash conversion: Operating cash flow declined even as net income increased, with accounts receivable creating a larger quarterly use of cash. Continued working-capital pressure could limit cash available for investment and capital returns.
- Higher borrowings alongside repurchases: Total bank credit lines and debt increased by approximately $417 million from fiscal year-end while year-to-date repurchases reached $450 million. Further increases could reduce balance-sheet flexibility.
- Execution of planned investments: The updated outlook includes limited Q4 growth investments intended to contribute in 2027. Their eventual return will depend on the company converting those expenditures into sustained sales and earnings growth.
Summary
Henry Schein’s Q3 2026 results combined moderate revenue growth with faster profit expansion, led by U.S. dental merchandise volume and market-share gains. Margin improvement, underlying adjusted EPS growth, and fewer diluted shares supported the higher earnings outlook, although cash conversion weakened and borrowings increased. The main points to monitor are whether dental growth remains durable, weaker businesses improve, and the company can deliver its raised guidance without additional tariff-related benefits.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.